Corvus Pharmaceuticals Inc (CRVS) - Net Assets
Based on the latest financial reports, Corvus Pharmaceuticals Inc (CRVS) has net assets worth $61.20 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($71.12 Million) and total liabilities ($9.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CRVS financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $61.20 Million |
| % of Total Assets | 86.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | -37.01% |
| 10-Year Change | -53.91% |
| Growth Volatility | 41.37 |
Corvus Pharmaceuticals Inc - Net Assets Trend (2014–2025)
This chart illustrates how Corvus Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore CRVS total asset value for the complete picture of this company's asset base.
Annual Net Assets for Corvus Pharmaceuticals Inc (2014–2025)
The table below shows the annual net assets of Corvus Pharmaceuticals Inc from 2014 to 2025. For live valuation and market cap data, see CRVS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $61.20 Million | +87.93% |
| 2024-12-31 | $32.57 Million | -15.81% |
| 2023-12-31 | $38.68 Million | -31.06% |
| 2022-12-31 | $56.12 Million | -42.25% |
| 2021-12-31 | $97.16 Million | +34.67% |
| 2020-12-31 | $72.15 Million | +1.46% |
| 2019-12-31 | $71.11 Million | -35.55% |
| 2018-12-31 | $110.34 Million | +30.06% |
| 2017-12-31 | $84.83 Million | -36.12% |
| 2016-12-31 | $132.80 Million | +527.00% |
| 2015-12-31 | $-31.10 Million | -19460.38% |
| 2014-12-31 | $-159.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Corvus Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41213200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.01% |
| Other Comprehensive Income | $-896.00K | -1.46% |
| Other Components | $474.39 Million | 775.08% |
| Total Equity | $61.20 Million | 100.00% |
Corvus Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Corvus Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WuXi Xinje Electric Co Ltd
SHG:603416
|
$1.25 Billion |
|
Ziff Davis Inc
NASDAQ:ZD
|
$1.25 Billion |
|
HyUnion Holding Co Ltd
SHE:002537
|
$1.25 Billion |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
|
$1.25 Billion |
|
SK Reit Co Ltd
KO:395400
|
$1.25 Billion |
|
Befesa SA
XETRA:BFSA
|
$1.25 Billion |
|
China Modern Dairy Holdings Ltd
F:07M
|
$1.25 Billion |
|
Jsti Group
SHE:300284
|
$1.25 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Corvus Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,568,000 to 61,205,000, a change of 28,637,000 (87.9%).
- Net loss of 15,283,000 reduced equity.
- Other comprehensive income increased equity by 392,000.
- Other factors increased equity by 43,528,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.28 Million | -24.97% |
| Other Comprehensive Income | $392.00K | +0.64% |
| Other Changes | $43.53 Million | +71.12% |
| Total Change | $- | 87.93% |
Book Value vs Market Value Analysis
This analysis compares Corvus Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 20.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-0.93 | $15.46 | x |
| 2015-12-31 | $-1.52 | $15.46 | x |
| 2016-12-31 | $8.61 | $15.46 | x |
| 2017-12-31 | $4.14 | $15.46 | x |
| 2018-12-31 | $4.01 | $15.46 | x |
| 2019-12-31 | $2.42 | $15.46 | x |
| 2020-12-31 | $2.45 | $15.46 | x |
| 2021-12-31 | $2.32 | $15.46 | x |
| 2022-12-31 | $1.21 | $15.46 | x |
| 2023-12-31 | $0.81 | $15.46 | x |
| 2024-12-31 | $0.53 | $15.46 | x |
| 2025-12-31 | $0.77 | $15.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Corvus Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-24.97%) is above the historical average (-50.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-160.10K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.22 Million |
| 2016 | -27.39% | 0.00% | 0.00x | 1.06x | $-49.66 Million |
| 2017 | -65.61% | 0.00% | 0.00x | 1.12x | $-64.15 Million |
| 2018 | -42.54% | 0.00% | 0.00x | 1.07x | $-57.97 Million |
| 2019 | -61.52% | 0.00% | 0.00x | 1.18x | $-50.86 Million |
| 2020 | -6.68% | 0.00% | 0.00x | 1.19x | $-12.04 Million |
| 2021 | -44.50% | 0.00% | 0.00x | 1.13x | $-52.96 Million |
| 2022 | -73.61% | 0.00% | 0.00x | 1.22x | $-46.92 Million |
| 2023 | -69.87% | 0.00% | 0.00x | 1.18x | $-30.90 Million |
| 2024 | -191.27% | 0.00% | 0.00x | 2.12x | $-65.55 Million |
| 2025 | -24.97% | 0.00% | 0.00x | 1.16x | $-21.40 Million |
Industry Comparison
This section compares Corvus Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Corvus Pharmaceuticals Inc (CRVS) | $61.20 Million | 0.00% | 0.16x | $1.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more